Cover Image

Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database

ObjectiveUsing the FDA adverse event reporting system (FAERS) database to analyze the safety profile of Dexmedetomidine and provide guidance for clinical application.MethodsData from the FAERS database from the first quarter of 2004 to the third quarter of 2023 were collected. Reporting odds ratio (...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yichun Shuai (Author), Zhe Chen (Author), Qiaoqian Wan (Author), Jinzheng Wu (Author), Xin Wang (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical adverse events to dexmedetomidine: a real-world drug safety study based on the FAERS database
by: Feng Liu, et al.
Published: (2024)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
by: Yan Wu, et al.
Published: (2023)

Adverse event profile of lorazepam: a real-world pharmacovigilance study using the FDA adverse event reporting system database
by: Zhengkang Su, et al.
Published: (2024)

Epirubicin and gait apraxia: a real-world data analysis of the FDA Adverse Event Reporting System database
by: Wei Wang, et al.
Published: (2023)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
by: Fan Zou, et al.
Published: (2023)

A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
by: Liyuan Liu
Published: (2024)

Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
by: Junwei Wang, et al.
Published: (2024)

Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Jiahong Zhong, et al.
Published: (2024)

Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database
by: Shangze Li, et al.
Published: (2024)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2023)

A real-world pharmacovigilance analysis for transthyretin inhibitors: findings from the FDA adverse event reporting database
by: Yuan Liu, et al.
Published: (2024)

Antifungal Drugs and Drug-Induced Liver Injury: A Real-World Study Leveraging the FDA Adverse Event Reporting System Database
by: Zhi-Xuan Zhou, et al.
Published: (2022)

Safety assessment of tranexamic acid: real-world adverse event analysis from the FAERS database
by: Ningsheng Tian, et al.
Published: (2024)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
by: Zhiwei Cui, et al.
Published: (2023)

A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam
by: Weizhen He, et al.
Published: (2024)

Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting system
by: Huqun Li, et al.
Published: (2024)

Assessing real-world safety of plecanatide: a pharmacovigilance study based on the FDA adverse event reporting system
by: Zhiyuan Zhang, et al.
Published: (2024)

Neratinib safety evaluation: real-world adverse event analysis from the FAERS database
by: Yunhe Fan, et al.
Published: (2024)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for denosumab
by: Yue He, et al.
Published: (2024)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib
by: Xusheng Zhang, et al.
Published: (2024)

Muscular toxicity of colchicine combined with statins: a real-world study based on the FDA adverse event reporting system database from 2004-2023
by: Ying Liu, et al.
Published: (2024)

The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system
by: Wei Wei, et al.
Published: (2024)

Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database
by: Shihao Chen, et al.
Published: (2024)

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system
by: Huqun Li, et al.
Published: (2023)

A real-world study of adverse drug reactions of two isocitrate dehydrogenase inhibitor based on the US FDA adverse event reporting system and VigiAccess databases
by: Mengmeng Peng, et al.
Published: (2024)

Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2023)

Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system
by: Qiong Jie, et al.
Published: (2024)

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system
by: Zhihong Fang, et al.
Published: (2023)

Contrastive analysis on the safety of brand and generic nebivolol: a real-world pharmacovigilance study based on the FDA adverse event reporting system
by: Hongli Wang, et al.
Published: (2024)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
by: Xue-Feng Jiao, et al.
Published: (2023)

Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database
by: Khalidah A. Alenzi, et al.
Published: (2024)

Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database
by: Chuanli Yang, et al.
Published: (2024)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
by: Jianxing Zhou, et al.
Published: (2022)

Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database
by: Ruixue Liu, et al.
Published: (2024)

A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS)
by: Dan Liu, et al.
Published: (2024)

A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system
by: Yiwen Wang, et al.
Published: (2024)

Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database
by: Dongxuan Li, et al.
Published: (2024)

Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database
by: Maoxia Fan, et al.
Published: (2024)

Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
by: Dan Zhao, et al.
Published: (2024)

Safety of tildrakizumab: a disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023
by: Jinger Lin, et al.
Published: (2024)